Hospital Acquired Infection Treatment

Global Hospital Acquired Infection Treatment Market to Reach US$45.5 Billion by 2030

The global market for Hospital Acquired Infection Treatment estimated at US$38.7 Billion in the year 2024, is expected to reach US$45.5 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Urinary Tract Infections, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$31.7 Billion by the end of the analysis period. Growth in the Ventilator-Associated Pneumonia segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.5 Billion While China is Forecast to Grow at 2.6% CAGR

The Hospital Acquired Infection Treatment market in the U.S. is estimated at US$10.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 2.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Hospital Acquired Infection Treatment Market - Key Trends & Drivers Summarized

Why Is Treatment for Hospital Acquired Infections Crucial?

Hospital Acquired Infections (HAIs) are infections that patients contract while receiving treatment in healthcare facilities, and they pose serious risks to patient health, prolonging hospital stays and complicating recovery. Common HAIs include infections like MRSA, Clostridioides difficile, and urinary tract infections, which can spread in healthcare environments without stringent hygiene practices. As healthcare facilities aim to improve patient outcomes, the importance of effective HAI treatments has grown, making infection control a top priority. The need to mitigate the spread of infections and improve patient safety has spurred advancements in HAI treatment, leading to more specialized therapies and preventive measures tailored to address these infections.

How Are Advancements in Treatment Methods Impacting HAI Management?

Innovations in HAI treatment have led to more effective options that target specific pathogens and improve patient recovery rates. Advances include new antibiotics and antiviral therapies that are tailored to resist resistant strains of bacteria, which are a significant challenge in HAI management. Other treatments, such as probiotics and bacteriophage therapy, offer alternatives to traditional antibiotics and help prevent microbial resistance. Additionally, hospitals are increasingly using advanced diagnostic tools, including rapid DNA-based tests, to quickly identify infections and select the most effective treatments. These advancements are revolutionizing infection control strategies, enabling healthcare providers to administer timely, effective care to reduce the spread of HAIs within hospitals.

Why Is There Growing Demand for HAI Treatment Solutions?

The rise in multidrug-resistant infections and increasing healthcare regulations have amplified the demand for HAI treatment solutions in hospitals and healthcare facilities. As healthcare-associated infections complicate patient care and drive up treatment costs, healthcare providers and regulatory agencies are enforcing stricter infection control protocols and treatment standards. This demand is fueled by an aging population, which is more susceptible to infections, as well as an increase in invasive procedures that carry infection risks. Hospitals are investing in comprehensive HAI treatment programs to not only enhance patient safety but also reduce the financial burdens associated with extended hospital stays and additional treatment requirements.

The Growth in the Hospital Acquired Infection Treatment Market Is Driven by Several Factors

The growth in the hospital acquired infection treatment market is driven by several factors, including advancements in antimicrobial treatments, stricter regulatory standards, and an aging population prone to infections. Technological advancements, such as rapid diagnostics and targeted therapies, have improved the efficiency of HAI treatments, enabling quicker and more precise responses to infections. Regulatory requirements and accreditation standards for infection control are prompting hospitals to adopt specialized HAI treatment solutions to meet compliance and improve patient care. Additionally, an increase in high-risk procedures, alongside the growing prevalence of resistant bacteria, has intensified the need for advanced infection control and treatment solutions, supporting continued market growth.

SCOPE OF STUDY:

The report analyzes the Hospital Acquired Infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Infection Type (Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Other Infection Types); Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment, Other Treatments)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories, Inc.
• Aridis Pharmaceuticals, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Cepheid, Inc.
• Cipla Ltd.
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Pfizer, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.